Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 869-874 , November 2008

Peripheral metabolism of [18F]FDDNP and cerebral uptake of its labelled metabolites

  • Gert Luurtsema

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 0 20 4443999.
    • ,
  • Robert C. Schuit

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Kevin Takkenkamp

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Mark Lubberink

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • N. Harry Hendrikse

      Affiliations

    • Clinical Pharmacology and Pharmacy, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Albert D. Windhorst

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Carla F.M. Molthoff

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Nelleke Tolboom

      Affiliations

    • Alzheimer Centre and Department of Neurology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Bart N.M. van Berckel

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Adriaan A. Lammertsma

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands

Received 20 June 2008 ,Revised 11 August 2008 ,Accepted 5 September 2008.

References 

  1. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–2663
  2. de Leon MJ, DeSanti S, Zinkowski R, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med. 2004;256:205–223
  3. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001;21:RC189
  4. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood–brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5:376–389
  5. Gillings NM, Bender D, Falborg L, Marthi K, Munk OL, Cumming P. Kinetics of the metabolism of four PET radioligands in living minipigs. Nucl Med Biol. 2001;28:97–104
  6. Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood–brain barrier: kinetics and metabolism in the rat. Nucl Med Biol. 2005;32:87–93
  7. Zoghbi SS, Shetty HU, Ichise M, et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med. 2006;47:520–527
  8. Greuter HN, van Ophemert PL, Luurtsema G, et al. Optimizing an online SPE-HPLC method for analysis of (R)-[11C]1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarb oxamide [(R)-[11C]PK11195] and its metabolites in humans. Nucl Med Biol. 2005;32:307–312
  9. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol. 2007;52:1505–1526
  10. Klok RP, Klein PJ, van Berckel BNM, Tolboom N, Lammertsma AA, Windhorst AD. Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)-methylamino-naphthalene ([18F]FDDNP). Appl Radiat Isot. 2008;66:203–207
  11. Michel C, Sibomana M, Bol A, Bernard X, Lonneux M, Defrise M, et al. Preserving Poisson characteristics of PET data with weighted OSEM reconstruction. In: IEEE Nucl Sci Symp Conf Rec M6-61. 1998;
  12. Liu J, Kepe V, Zabjek A, et al. High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration. Mol Imaging Biol. 2007;9:6–16
  13. Lubberink M, Luurtsema G, van Berckel BN, et al. Development of a tracer kinetic model for the analysis of (R)-[11C]verapamil PET data. J Cereb Blood Flow Metab. 2005;25:S608
  14. Maqsood Y, Boellaard R, van Berckel BNM, Tolboom N, Luurtsema G, Dijkstra AA, et al. Optimal tracer kinetic model for analysis of [18F]FDDNP studies. Mol Imaging Biol. 2008;[under revision]
  15. Cai LS, Chin FT, Pike VW, et al. Synthesis and evaluation of two F-18-labeled 6-iodo-2-(4′-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease. J Med Chem. 2004;47:2208–2218

☆ This work was funded in part by the EU FP6 project DiMI, LSHB-CT-2005-512146.

PII: S0969-8051(08)00181-9

doi: 10.1016/j.nucmedbio.2008.09.002

Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 869-874 , November 2008

Article Tools

* Image Usage & Resolution